Ergothioneine is a credible healthy-aging research target, but no controlled human trial has shown that it extends lifespan or broadly slows aging.
| Evidence type | What it shows | Confidence |
|---|---|---|
| Human RCTs | Limited controlled human evidence; topic-specific findings require replication. | |
| Observational human | Associations may exist; causality is unresolved. | |
| Animal | Signals may support human research. | |
| Laboratory | Mechanistic findings do not establish a clinical benefit. |
What attracts researchers
Ergothioneine is diet-derived, actively transported and retained in certain tissues. Blood levels have also been associated with age and health measures in observational work. Together, those features make it a useful candidate for aging research.
The lifespan headline needs context
A 2024 study reported longer lifespan and healthier functional measures in male mice given ergothioneine from early life. That is a meaningful preclinical result.
Mouse lifespan experiments are not human longevity trials. Species, dose scaling, treatment timing and controlled laboratory conditions prevent a direct translation to consumer outcomes.
What should happen next
Useful human trials would prespecify functional outcomes, measure baseline ergothioneine status and diet, report adherence and adverse events, and run long enough to distinguish a durable effect from normal variation.
Primary references
Reference list last checked Aug. 22, 2026.
Educational information only. This page does not provide personalized medical advice.
Read the full disclaimer →